Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
BUSINESS
Trodelvy Launch on Horizon, Gilead Japan to Hire Oncology Reps from Early 2024
Gilead Sciences will set out for an extensive recruitment drive to take on oncology-specialized sales reps in Japan from early next year, as it gears up for the targeted rollout of Trodelvy (sacituzumab govitecan-hziy) in 2024 for the treatment of…
To read the full story
Related Article
BUSINESS
- Global PIII Trial Halted for Arcus-Partnered TIGIT Drug: Taiho
December 16, 2025
- Vyvdura Now Available in Prefilled Syringe: Argenx Japan
December 16, 2025
- AbbVie Japan Seeks Rinvoq’s Broader Label for Alopecia Areata
December 16, 2025
- AbbVie Files Atogepant for Acute Migraine Attacks in Japan
December 16, 2025
- Pfizer Targets Double-Digit Oncology Growth in Japan over Next 5 Years
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…